ABSTRACT
The symptoms of Eosinophilic esophagitis (EoE) are similar to gastroesophageal reflux disease (GERD), although the clinical manifestations of EoE can vary with age. The primary differential diagnosis for EoE is GERD, which may be differentiated histologically by changes localized to the distal esophagus, rather than the entire esophagus. EoE has a nearly worldwide distribution and has been reported in various countries in North America, South America, Asia, Europe, and Australia. The recognition of key modulators of eosinophil recruitment and function has important clinical implications. In addition to being potential targets for drug development, Numerous inflammatory mediators may also have a future role in the diagnosis and monitoring of the disease. Mucosal biopsy specimens should be obtained from the proximal and distal esophagus. Emerging data support a potential role of interleukin-5 biologic agents, such as reslizumab or mepolizumab, in the treatment of EoE.
